Χώρα: Καναδάς
Γλώσσα: Αγγλικά
Πηγή: Health Canada
ABACAVIR (ABACAVIR SULFATE); LAMIVUDINE; ZIDOVUDINE
APOTEX INC
J05AR04
ZIDOVUDINE, LAMIVUDINE AND ABACAVIR
300MG; 150MG; 300MG
TABLET
ABACAVIR (ABACAVIR SULFATE) 300MG; LAMIVUDINE 150MG; ZIDOVUDINE 300MG
ORAL
60
Prescription
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS
Active ingredient group (AIG) number: 0345541001; AHFS:
APPROVED
2013-11-08
Page 1 of 45 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-ABACAVIR-LAMIVUDINE Abacavir and Lamivudine Tablets 600 mg abacavir (as abacavir sulfate) and 300 mg lamivudine Antiretroviral Agent Manufacturer’s Standard Date of Revision: December 27, 2019 Submission Control No: 233546 APOTEX INC. 150 SIGNET DRIVE TORONTO, ONTARIO M9L 1T9 Page 2 of 45 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 3 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................. 10 DRUG INTERACTIONS ................................................................................................. 13 DOSAGE AND ADMINISTRATION ............................................................................. 16 OVERDOSAGE ................................................................................................................ 17 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 17 STORAGE AND STABILITY ......................................................................................... 20 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 21 PART II: SCIENTIFIC INFORMATION ............................................................................... 22 PHARMACEUTICAL INFORMATION ......................................................................... 22 CLINICAL TRIALS ......................................................................................................... 24 M Διαβάστε το πλήρες έγγραφο